Werewolf Therapeutics
Filed with the SEC on · accession 0001140361-26-043046
HOWL filed a S-4 (s-4) with the SEC on Nov 10, 2026. A report the company filed with the SEC (the US market regulator). The stock moved -4.0% by the first close after the filing.
Werewolf Therapeutics filed an amended S-4 registration statement for its proposed merger with Ambros Therapeutics, in which Ambros will become a wholly owned subsidiary of Werewolf and Werewolf will be renamed Ambros Therapeutics, Inc.
Close before
$1.01
Nov 9, 2026
First close after
-3.96%
$0.97
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for HOWL, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for HOWL?
Click hereHOWL filed a S-4 (Acquisition). Werewolf Therapeutics filed an amended S-4 registration statement for its proposed merger with Ambros Therapeutics, in which Ambros will become a wholly owned subsidiary of Werewolf and Werewolf will be renamed Ambros Therapeutics, Inc.
A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A S-4 (s-4): A report the company filed with the SEC (the US market regulator).
HOWL closed at $1.01 before the filing and $0.97 on Nov 10, 2026 (-3.96%).
Get alerts when HOWL files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days